# Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT

> **NCT05084027** · PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 50 (estimated)

## Conditions studied

- Hematologic Malignancy
- Older Patients
- Allogeneic Hematopoietic Stem Cell Transplantation

## Interventions

- **COMBINATION_PRODUCT:** venetoclax combining with fludarabine and melphalan

## Key facts

- **NCT ID:** NCT05084027
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-07
- **Primary completion:** 2022-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2021-10-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05084027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05084027, "Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05084027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*